Предикторы терапевтической динамики когнитивных нарушений при депрессивных расстройствах непсихотического уровня

Полный текст:   Только для подписчиков

Рекомендуемое оформление библиографической ссылки:

Федорова А.И., Ахапкин Р.В., Файзуллоев А.З. Предикторы терапевтической динамики когнитивных нарушений при депрессивных расстройствах непсихотического уровня // Российский психиатрический журнал. 2019. №1. С. 47-57.

Аннотация

В научном обзоре с целью анализа российских и зарубежных публикаций, посвящённых особенностям терапевтической динамики когнитивных нарушений при униполярных депрессивных расстройствах, было изучено более 250 источников, из которых в обзор включено 60 публикаций. Показано, что симптомы когнитивных нарушений сохраняются, несмотря на лечение антидепрессантами и достижение пациентами синдромальной ремиссии, ухудшающими их социальное функционирование. Описаны вероятные предикторы терапевтической динамики когнитивных нарушений, имеющие свои закономерности, отличные от аффективных расстройств. Это определяет новизну работы и стратегию дальнейшего исследования предикторов когнитивных нарушений с целью оптимизации выбора адекватной терапии соответствующего контингента пациентов.

Ключевые слова депрессия; когнитивные нарушения; антидепрессанты

Литература

1. Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016;388(10053):1545–602. DOI: 10.1016/S0140-6736(16)31678-6 2. Gualtieri CT, Johnson LG, Benedict KB. Neurocognition in depression: patients on and off medication versus healthy comparison subjects. J Neuropsychiatry Clin Neurosci. 2006;18(2):217–25. DOI: 10.1176/appi.neuropsych.18.2.217 3. Conradi HJ, Ormel J, De Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011;41(6):1165–74. DOI: 10.1017/S0033291710001911 4. Kanaeva LS. Prognosticheskaya rol’ kliniko-sotsial’nykh faktorov v otsenke effektivnosti farmakoterapii u bol’nykh s nepsikhoticheskimi depressiyami. Farmateka. 2014;7(14):45–52. Russian. 5. Bora E, Harrison BJ, Yücel M, et al. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol Med. 2013;43(10):2017–26. DOI: 10.1017/S0033291712002085 6. Kraepelin E. Lectures on Clinical Psychiatry, by Dr. Emil Kraepelin. Wood; 1917. p. 1–10. 7. Roiser JP, Sahakian BJ. Hot and cold cognition in depression. CNS Spectr. 2013;18(3):139–49. DOI: 10.1017/S1092852913000072 8. Shmukler AB. [Cognitive impairment in depressive syndrom]. Sotsial’naya i klinicheskaya psikhiatriya. 2016;26(1):72–6. Russian. 9. Derakshan N, Eysenck MW. Introduction to the special issue: emotional states, attention, and working memory. Cogn Emot. 2010;24(2):189–99. DOI: 10.1080/02699930903412120 10. Murphy FC, Sahakian BJ, Rubinsztein JS, et al. Emotional bias and inhibitory control processes in mania and depression. Psychol Med. 1999;29(6):1307–21. PMID: 10616937 11. Wells TT, Beevers CG. Biased attention and dysphoria: Manipulating selective attention reduces subsequent depressive symptoms. Cogn Emot. 2010;24(4):719–28. DOI: 10.1080/02699930802652388 12. Watson D, Clark LA. Negative affectivity: the disposition to experience aversive emotional states. Psychol Bull. 1984;96(3):465. DOI: 10.1037/0033-2909.96.3.465 13. Krasnov VN, Alfimova MV, Melnikova TS, et al. [Relationships Between Cognitive and Emotional Disturbances in Depressions]. Doktor.Ru. 2013;5(83):1–6. Russian. 14. Rock PL, Roiser JP, Riedel WJ, et al. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44(10):2029–40. DOI: 10.1017/S0033291713002535 15. Hammar A, Ardal G. Cognitive functioning in major depression – a summary. Front Hum Neurosci. 2009;3:26. DOI: 10.3389/neuro.09.026.2009 16. Tavares JVT, Clark L, Cannon DM, et al. Distinct profiles of neurocognitive function in unmedicated unipolar depression and bipolar II depression. Biol Psychiatry. 2007;62(8):917–24. DOI:10.1016/j.biopsych.2007.05.034 17. Fitzgerald PB, Srithiran A, Benitez J, et al. An fMRI study of prefrontal brain activation during multiple tasks in patients with major depressive disorder. Hum Brain Mapp. 2008;29(4):490–501. DOI: 10.1002/hbm.20414 18. Phan KL, Fitzgerald DA, Nathan PJ, et al. Neural substrates for voluntary suppression of negative affect: a functional magnetic resonance imaging study. Biol Psychiatry. 2005;57(3):210–9. DOI: 10.1016/j.biopsych.2004.10.030 19. Volel BA, Akhapkin RV, Ustyuzhanin DV, et al. [Neuroimaging techniques in the diagnosis and treatment of depressive disorders]. Zh Nevrol Psikhiatr Im SS Korsakova. 2017;117(2):163–8. Russian. DOI: 10.17116/jnevro201711721163-168 20. Liu CH, Jing B, Ma X, et al. Voxel-based morphometry study of the insular cortex in female patients with current and remitted depression. Neuroscience. 2014;262:190–9. DOI: 10.1016/j.neuroscience.2013.12.058 21. McKinnon MC, Yucel K, Nazarov A, et al. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci. 2009;34(1):41–54. PMID: 19125212 22. Penrod NM, Cowper-Sallari R, Moore JH. Systems genetics for drug target discovery. Trends Pharmacol Sci. 2011;32(10):623–30. DOI: http://10.1016/j.tips.2011.07.002 23. McIntyre RS, Lee Y. Cognition in major depressive disorder: a ‘Systemically Important Functional Index’ (SIFI). Curr Opin Psychiatry. 2016;29(1):48–55. PMID: 26575300, DOI: 10.1097/YCO.0000000000000221 24. Larochette AC, Harrison AG, Rosenblum Y, et al. Additive neurocognitive deficits in adults with attention-deficit/hyperactivity disorder and depressive symptoms. Arch Clin Neuropsychol. 2011;26(5):385–95. DOI: 10.1093/arclin/acr033 25. Akhapkin RV. [Cognitive impairment in major depression: an analysis of problems and potential solutions (review)]. Sovremennaya terapiya psikhicheskikh rasstroistv. 2015;(4):2–7. Russian. 26. Yanushko MG, Shamanina MV, Ivanov MV. [Cognitive functioning parameters in patients with recurrent depressive disorder]. Sotsial’naya i klinicheskaya psikhiatriya. 2017;27(3):26–31. Russian. 27. Kursakov AA. Kharakteristika depressivnykh sostoyanii u bol’nykh pervichnoi mediko-sanitarnoi pomoshchi (klinicheskie, neirokognitivnye, lichnostnye proyavleniya i terapevticheskie aspekty) [PhD thesis]. [Moscow (Russia)]: Natsional’nyi meditsinskii issledovatel’skii tsentr psikhiatrii i narkologii [National Medical Research Center for Psychiatry and Narcology]; 2017. 17 p. Russian. 28. Gallagher D, Kiss A, Lanctot K, et al. Depressive symptoms and cognitive decline: a longitudinal analysis of potentially modifiable risk factors in community dwelling older adults. J Affect Disord. 2016;190:235–40. DOI: 10.1016/j.jad.2015.09.046 29. Gildengers AG, Butters MA, Chisholm D, et al. Cognition in older adults with bipolar disorder versus major depressive disorder. Bipolar Disord. 2012;14(2):198–205. DOI: 10.1111/j.1399-5618.2012.00995.x 30. Thomas AJ, Gallagher P, Robinson LJ, et al. A comparison of neurocognitive impairment in younger and older adults with major depression. Psychol Med. 2009;39(5):725–33. DOI: 10.1017/S0033291708004042 31. Withall A, Harris LM, Cumming SR. A longitudinal study of cognitive function in melancholic and non-melancholic subtypes of major depressive disorder. J Affect Disord. 2010;123(1):150–7. DOI: 10.0.3.248/j.jad.2009.07.012 32. McDermott LM, Ebmeier KP. A meta-analysis of depression severity and cognitive function. J Affect Disord. 2009;119(1):1–8. DOI: 10.1016/j.jad.2009.04.022 33. Liu IC, Chiu CH, Yang TT. The effects of gender and a co-occurring depressive disorder on neurocognitive functioning in patients with alcohol dependence. Alcohol Alcohol. 2010;45(3):231–6. DOI: 10.1093/alcalc/agq016 34. Baune BT, McAfoose J, Leach G, et al. Impact of psychiatric and medical comorbidity on cognitive function in depression. Psychiatry Clin Neurosci. 2009;63(3):392–400. DOI: 10.1111/j.1440-1819.2009.01971.x 35. Wang XD, Rammes G, Kraev I, et al. Forebrain CRF1 modulates early-life stress-programmed cognitive deficits. J Neurosci. 2011;31(38):13625–34. DOI: 10.1523/JNEUROSCI.2259-11.2011 36. Holmes A, Wellman CL. Stress-induced prefrontal reorganization and executive dysfunction in rodents. Neurosci Biobehav Rev. 2009;33(6):773–83. DOI: 10.1016/j.neubiorev.2008.11.005 37. Bekker RA, Bykov YuV. [On the role of neuroendocrine abnormalities in the pathogenesis of cognitive dysfunction in major depressive disorder (a literature review with authors’ comments)]. Consilium Medicum. 2016;18(4):57–61. Russian. 38. Maki PM. Hormone therapy and cognitive function: is there a critical period for benefit? Neuroscience. 2006;138(3):1027–30. DOI: 10.1016/j.neuroscience.2006.01.001 39. Lisofsky N, Martensson J, Eckert A, et al. Hippocampal volume and functional connectivity changes during the female menstrual cycle. Neuroimage. 2015;118:154–62. DOI: 10.1016/j.neuroimage.2015.06.012 40. Fominova UN, Gurina OI, SHepeleva II, et al. Neirotroficheskii faktor golovnogo mozga: struktura i vzaimodeistvie s retseptorami [Brain-derived Neurotrophic Factor: Structure and Interaction with Receptors]. Rossiiskii psikhiatricheskii zhurnal [Russian journal of psychiatry]. 2018;(4):64–72. Russian. 41. Diniz BS. Decreased Brain-Derived Neurotrophic Factor (BDNF) in Older Adults with Bipolar Disorder: Meaning and Utility? Am J Geriatr Psychiatry. 2016;24(8):602–3. DOI: 10.1016/j.jagp.2016.03.003 42. Vaidya CJ, Stollstorff M. Cognitive neuroscience of attention deficit hyperactivity disorder: current status and working hypotheses. Dev Disabil Res Rev. 2008;14(4):261–7. DOI: 10.1002/ddrr.40 43. Stanton WR, McGee RO, Silva PA. A longitudinal study of the interactive effects of perinatal complications and early family adversity on cognitive ability. Aust Paediatr J. 1989;25(3):130–3. DOI: 10.1111/j.1440-1754.1989.tb01435.x 44. Herrmann LL, Le Masurier M, Ebmeier KP. White matter hyperintensities in late life depression: a systematic review. J Neurol Neurosurg Psychiatry. 2008;79(6):619–24. DOI: 10.1136/jnnp.2007.124651 45. Wagner S, Doering B, Helmreich I, et al. A meta-analysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepressant treatment. Acta Psychiatr Scand. 2012;125(4):281–92. DOI: 10.1111/j.1600-0447.2011.01762.x 46. Mosolov SN, Kostyukova EG. Lecheniye bol’nykh s rekurrentnym depressivnym rasstroystvom. In: Ed. by Aleksandrovskiy YA, Neznanov NG. Neznanova Psikhiatriya. Natsional’noe rukovodstvo. Moscow; 2018:347–78. Russian. 47. Lee YS, Silva AJ. The molecular and cellular biology of enhanced cognition. Nat Rev Neurosci. 2009;10(2):126. PMID:19153576, DOI: 10.1038/nrn2572 48. Keefe RS, McClintock SM, Roth RM, et al. Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. J Clin Psychiatry. 2014;75(8):864–76. PMID:25099527, DOI: 10.4088/JCP.13r08609 49. Culang-Reinlieb ME, Sneed JR, Keilp JG, et al. Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline. Int J Geriatr Psychiatry. 2012;27(8):777–84. DOI: 10.1002/gps.2783 50. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007;164(6):900–9. DOI: 10.1176/appi.ajp.164.6.900 51. Greer TL, Sunderajan P, Grannemann BD, et al. Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction? Depress Res Treat. 2014;2014:1–13. DOI: 10.1155/2014/627863 52. Herrera-Guzmán I, Gudayol-Ferré E, Herrera-Abarca JE, et al. Major depressive disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with major depressive disorder in recovery. J Affect Disord. 2010;123(1):341–50. DOI: 10.1016/j.jad.2009.10.009 53. Mahableshwarkar AR, Zajecka J, Jacobson W, et al. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015;40(8):2025–37. PMID: 25687662, DOI: 10.1038/npp.2015.52 54. Ferguson JM, Wesnes KA, Schwartz GE. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol. 2003;18(1):9–14. DOI: 10.1097/00004850-200301000-00002 55. Miskowiak KW, Ott CV, Petersen JZ, et al. Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field. Eur Neuropsychopharmacol. 2016;26(12):1845–67. DOI: 10.1016/j.euroneuro.2016.09.641 56. Blackburn IM, Eunson KM, Bishop S. A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both. J Affect Disord. 1986;10(1):67–75. DOI: 10.1016/0165-0327(86)90050-9 57. Mayberg HS, Brannan SK, Tekell JL, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry. 2000;48(8):830–43. DOI: 10.1016/S0006-3223(00)01036-2 58. Köhler S, Hoffmann S, Unger T, et al. Effectiveness of cognitive–behavioral therapy plus pharmacotherapy in inpatient treatment of depressive disorders. Clin Psychol Psychother. 2013;20(2):97–106. DOI: 10.1002/cpp.795 59. Lapin IP. Platsebo i terapiya. Saint Petersburg; 2000. 223 p. Russian.



DOI: http://dx.doi.org/10.24411/1560-957X-2019-11907

Метрики статей

Загрузка метрик ...

Metrics powered by PLOS ALM